China targets 25% of global first-in-class drugs by 2030 in new biopharma plan

China's new five-year plan for biomedicine sets a goal of securing at least 25% of the world's first-in-class drugs by 2030, aiming to 'firmly rank at the global forefront' in R&D and applications. The plan signals a strategic push to enhance core competitiveness and international influence in the sector. This is a policy announcement with no immediate market impact, but it underscores China's long-term ambition to lead in high-tech industries.